BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia

Published:2014-10-20 Issue:11 Volume:124 Page:5074-5084
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Yaktapour Niuscha,Meiss Frank,Mastroianni Justin,Zenz Thorsten,Andrlova Hana,Mathew Nimitha R.,Claus Rainer,Hutter Barbara,Fröhling Stefan,Brors Benedikt,Pfeifer Dietmar,Pantic Milena,Bartsch Ingrid,Spehl Timo S.,Meyer Philipp T.,Duyster Justus,Zirlik Katja,Brummer Tilman,Zeiser Robert

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference48 articles.

1. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

3. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

4. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

5. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzyme Is the Name—Adapter Is the Game;Cells;2024-07-25

2. Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies;American Journal of Hematology;2024-03-05

3. BRAF — a tumour-agnostic drug target with lineage-specific dependencies;Nature Reviews Clinical Oncology;2024-01-26

4. A renewed concept on the MAPK signaling pathway in cancers: Polyphenols as a choice of therapeutics;Pharmacological Research;2022-10

5. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation;Frontiers in Oncology;2022-07-27